EVALUATION OF DRUG USE OF CHEMOTHERAPY PATIENTS IN THE INSTALLATION OF CERVICAL CANCER HOSPITAL Hospital Dr Moewardi PERIOD JULY - SEPTEMBER IN 2012
ABSTRACT: Cervical cancer is one of leading causes of death related cancer of women worldwide. Purpose of this study was to evaluate chemotherapy drugs in patients with cervical cancer in inpatient RSUD Dr. Moewardi in the period July - September 2012 in terms of the right drug, the right indication, the right patient and the right dose. This study uses descriptive non-experimental research design. Retrieval of data performed retrospectively to patient medical records in 52 cervical cancer patients in the inpatient RSUD Dr. Moewardi the period July to September 2012 that getting chemotherapy. Types of standards that are used are National Comprehensive Cancer Network Clinical Practice Guideline in Oncology (NCCN) version 1.2011 and Protocol use of chemotherapy at the RSUD Dr. Moewardi. The results mentioned cervical cancer patients in inpatient RSUD Dr. Moewardi 57.7% is the patient referral. Age distribution of patients found 59.6% of patients were in the age range of 50 - 64 years. Cycle variation 27.5% of patients undergoing chemotherapy cycle 1. Variations premedication used was Ondansetron. The average length of a maximum of 8 ± 3.2 days. Chemotherapy regimens most widely used drug combination is 86.60% Cisplatin and 5-FU. Appropriateness of indications for drugs 100%, 100% accuracy of the drug, patients 100% accuracy, and precision dose of 92.14% ± 15.7%.
